Featured Content

Dean, Gesme, MD
FACP FACPE FASCO President, Minnesota Oncology

Eagle Pharmaceuticals Sues FDA Over Marketing Exclusivity Denial

(Bloomberg BNA/Health Care Blog) Apr 29, 2016 - Eagle Pharmaceuticals has the FDA in its crosshairs: it’s suing the agency over its decision to deny Eagle’s cancer treatment Bendeka seven years of orphan drug marketing exclusivity.

Commentary: This will be a precedence setting legal dispute over the application of the Orphan Drug Act to provide patent protection...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

CMS Feels the Heat to Change Medicare Part B Drug Pay Plan

(Modern Healthcare) May 4, 2016 - The pressure is on for the CMS to transform or even drop its recently proposed plan to change the way it pays hospitals and doctors for outpatient drugs covered by Medicare Part B.
read article »

Laser Brain Cancer Treatment May Bring Extra Advantage

(Reuters) May 4, 2016 - Neurosurgeons using lasers to treat brain cancer have discovered that the technique breaks down the blood-brain barrier, a finding that could lead to new treatment options for patients with the deadly disease.
read article »

USPSTF Re-evaluates PSA Testing; Here's Their Plan

(Medscape Medical News) May 4, 2016 - The US Preventive Services Task Force (USPSTF) is updating its controversial guidance about prostate cancer screening, and a final research plan was published online last week.
read article (free registration required) »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Eagle Pharmaceuticals Sues FDA Over Marketing Exclusivity Denial (Bloomberg BNA/Health Care Blog)

This will be a precedence setting legal dispute over the application of the Orphan Drug Act to provide patent protection...posted by: Dean, Gesme, MD

Opposition Building On Capitol Hill To HHS Plan To Cut Medicare Payments For Some Drugs (KHN Morning Briefing)

We all know that the primary objective here is to cut cost. The question that is being evaded is cutting costs...posted by: Winston, Wong, PharmD

Largest Study Of Patients With Early Stage II Testicular Cancer Shows Radiation Therapy Is More Effective Than Chemotherapy (ESTRO 35)

Using NCDB, authors show that radiotherapy is superior to chemotherapy for stage IIa testicular seminoma. While...posted by: Howard Sandler, MD, MS, FASTRO

A Misguided Experiment? (ACCCBuzz)

The problem with this proposal is that it is the traditional knee-jerk reaction. In order to cut cost, we lower...posted by: Winston Wong, PharmD

Via Oncology Launches Expanded Support for CMMI OCM Practices (PRWEB)

This expansion of services to support the oncology practice by Via Oncology confirms the concept that clinical...posted by: Winston Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Navigating Cancer has 1 job posted.


Bayer Pharmaceuticals has 1 job posted.


Touchpoint Solutions has over 20 jobs posted.


Check out the OBR Job Board here.





The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
XLRN +8.95%
GHDX +7.79%
CTIC +6.96%
TKMR -10.99%
MGNX -6.68%
BCRX -6.67%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: May 16, 2016
Company: Eisai, Inc.
Product: Lenvima® (lenvatinib)

Date: June 1, 2016
Company: Advanced Accelerator Application SA
Product: Somakit-TATA (kit for the Preparation of 68Ga-DOTATATE for Injection)

Date: June 4, 2016
Company: ARIAD Pharmaceuticals
Product: brigatinib

See All OBR Radar items»